HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.